Halter Ferguson Financial Inc. Lowers Position in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA)

Halter Ferguson Financial Inc. lessened its position in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) by 36.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 240,818 shares of the company’s stock after selling 135,896 shares during the quarter. MAIA Biotechnology makes up about 0.2% of Halter Ferguson Financial Inc.’s investment portfolio, making the stock its 22nd largest holding. Halter Ferguson Financial Inc.’s holdings in MAIA Biotechnology were worth $477,000 at the end of the most recent reporting period.

Separately, Geode Capital Management LLC increased its holdings in shares of MAIA Biotechnology by 22.9% in the 3rd quarter. Geode Capital Management LLC now owns 192,563 shares of the company’s stock worth $541,000 after purchasing an additional 35,821 shares in the last quarter. 5.65% of the stock is currently owned by institutional investors.

MAIA Biotechnology Trading Up 7.7 %

MAIA Biotechnology stock opened at $1.67 on Tuesday. The company has a market cap of $43.69 million, a price-to-earnings ratio of -1.21 and a beta of 0.20. The business has a fifty day simple moving average of $1.92. MAIA Biotechnology, Inc. has a 12 month low of $1.46 and a 12 month high of $5.99.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.